- Home
- DAWN vs EML Comparison
DAWN vs EML Comparison
Compare DAWN & EML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- EML
- Stock Information
- Founded
- DAWN 2018
- EML 1858
- Country
- DAWN United States
- EML United States
- Employees
- DAWN N/A
- EML N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- EML Industrial Machinery/Components
- Sector
- DAWN Health Care
- EML Consumer Discretionary
- Exchange
- DAWN Nasdaq
- EML Nasdaq
- Market Cap
- DAWN 658.9M
- EML 144.5M
- IPO Year
- DAWN 2021
- EML N/A
- Fundamental
- Price
- DAWN $6.90
- EML $24.00
- Analyst Decision
- DAWN Strong Buy
- EML
- Analyst Count
- DAWN 7
- EML 0
- Target Price
- DAWN $31.57
- EML N/A
- AVG Volume (30 Days)
- DAWN 1.3M
- EML 12.1K
- Earning Date
- DAWN 07-29-2025
- EML 08-05-2025
- Dividend Yield
- DAWN N/A
- EML 1.82%
- EPS Growth
- DAWN N/A
- EML N/A
- EPS
- DAWN N/A
- EML N/A
- Revenue
- DAWN $161,922,000.00
- EML $271,440,503.00
- Revenue This Year
- DAWN $17.98
- EML $1.56
- Revenue Next Year
- DAWN $49.50
- EML $7.00
- P/E Ratio
- DAWN N/A
- EML $11.55
- Revenue Growth
- DAWN N/A
- EML 8.15
- 52 Week Low
- DAWN $6.08
- EML $19.06
- 52 Week High
- DAWN $16.76
- EML $35.03
- Technical
- Relative Strength Index (RSI)
- DAWN 58.34
- EML 59.25
- Support Level
- DAWN $6.52
- EML $24.04
- Resistance Level
- DAWN $7.24
- EML $24.70
- Average True Range (ATR)
- DAWN 0.26
- EML 0.57
- MACD
- DAWN 0.07
- EML 0.12
- Stochastic Oscillator
- DAWN 78.37
- EML 84.25
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.